Compassionate use of ruxolitinib in patients with SARS‐Cov‐2 infection not on mechanical ventilation: Short‐term effects on inflammation and ventilation

ABSTRACT: Ruxolitinib is an anti‐inflammatory drug that inhibits the Janus kinase‐signal transducer (JAK‐STAT) pathway on the surface of immune cells. The potential targeting of this pathway using JAK inhibitors is a promising approach in patients affected by coronavirus disease 2019 (COVID‐19). Rux...

Descripción completa

Detalles Bibliográficos
Autores principales: Mortara, Andrea, Mazzetti, Simone, Margonato, Davide, Delfino, Pietro, Bersano, Chiara, Catagnano, Francesco, Lauriola, Marinella, Grosso, Paolo, Perseghin, Gianluca, Ippoliti, Giovanbattista
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212747/
https://www.ncbi.nlm.nih.gov/pubmed/33403775
http://dx.doi.org/10.1111/cts.12971

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212747/
https://www.ncbi.nlm.nih.gov/pubmed/33403775
http://dx.doi.org/10.1111/cts.12971

Ejemplares similares